Inactive Instrument

InDex Pharmaceuticals Holding AB Stock Nasdaq Stockholm

Equities

Pharmaceuticals

End-of-day quote Nasdaq Stockholm
- SEK - Intraday chart for InDex Pharmaceuticals Holding AB
Sales 2024 * - Sales 2025 * - Capitalization 175M 1.92B
Net income 2024 * -259M -2.83B Net income 2025 * -221M -2.42B EV / Sales 2024 * -
Net Debt 2024 * 86.32M 944M Net Debt 2025 * 306M 3.35B EV / Sales 2025 * -
P/E ratio 2024 *
-0.67 x
P/E ratio 2025 *
-0.8 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 62.47%
More Fundamentals * Assessed data
Index Pharmaceuticals Holding AB Announces Board Resignations CI
InDex Pharmaceuticals CEO, CFO to Step Down as Operations Cease MT
Index Pharmaceuticals Holding AB Announces Resignation of Johan Giléus as Deputy CEO CI
InDex Pharmaceuticals Holding AB Announces Resignation of Jenny Sundqvist as CEO, Effective September 26, 2024 CI
InDex Pharmaceuticals Holding AB Announce Resignation of Johan Giléus as CFO, Effective September 26, 2024 CI
InDex Pharmaceuticals Launches Strategic Review Amid Decision to Stop Cobitolimod Development MT
InDex Pharmaceuticals Holding AB Discontinues the Development of Cobitolimod CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
InDex Pharmaceuticals Holding AB Discontinues Cobitolimod Phase III Program CI
InDex Pharmaceuticals Holding AB Announces Composition of the Nomination Committee CI
InDex Pharmaceuticals Obtains South Korean Patent for Inflammatory Bowel Disease Drug Candidate MT
InDex Pharmaceuticals Holding AB Receives New Patent for Cobitolimod in South Korea CI
InDex Pharmaceuticals Holding AB Announces All Patients Needed for the Cobitolimod Dose Selection Milestone Have Completed Induction Study 1 of the Phase III Program Conclude CI
More news
Managers TitleAgeSince
Chief Executive Officer 53 22-12-31
Director of Finance/CFO 59 17-04-30
Chief Tech/Sci/R&D Officer 45 -
Members of the board TitleAgeSince
Director/Board Member 74 15-12-31
Director/Board Member 68 10-12-31
Chairman 72 10-12-31
More insiders
InDex Pharmaceuticals Holding AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused in pharmaceuticals development. The Company's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The Company also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn's disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.
Calendar
More about the company